# OnCo record rtog-9202 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/rtog-9202/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "rtog-9202" ;
  schema:name "RTOG 92-02"@en ;
  schema:alternateName "RTOG 9202"@en, "RTOG 92-02"@en ;
  schema:description "Two extra years of hormone therapy after radiotherapy improved every measure of cancer control, but only men with the most aggressive tumours lived longer for it."@en ;
  schema:url <https://onco.cc/trials/rtog-9202/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.2007.14.9021> ;
  onco:status "mixed" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-high-risk/> ;
  onco:technologies <https://onco.cc/technologies/androgen-deprivation/>, <https://onco.cc/technologies/imrt-igrt/> ;
  onco:drugs <https://onco.cc/drugs/goserelin/>, <https://onco.cc/drugs/flutamide/> ;
  onco:companies <https://onco.cc/companies/nrg-oncology/> ;
  onco:terms <https://onco.cc/terms/adt/>, <https://onco.cc/terms/gleason-grade-group/>, <https://onco.cc/terms/hormone-therapy/> ;
  onco:trials <https://onco.cc/trials/eortc-22961/>, <https://onco.cc/trials/dart-01-05-gicor/>, <https://onco.cc/trials/rtog-9408/> .